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https://doi.org/10.1016/j.stemcr.2018.10.005A feature distinguishing humanhematopoietic and epithelial stem
cells from other equally fascinating stem cells is perhaps their
easier translation into a clinical setting. We have devoted nearly
our entire scientific career in trying to turn our understanding
of epithelial stem cell biology into something that could help
people suffering from virtually untreatable diseases of squamous
epithelia. We have done that as a team, together with our
numerous students, postdocs, technicians and valuable collabora-
tors, clinicians, regulators, and, lately, industrial partners. We had
rewarding successes and burning failures, but we always did our
best. This award, given by friends and colleagues deserving it
more than us, has been the most important recognition of our
work. Below, we summarize our story.A few months ago, we reported on the regeneration of
virtually the entire epidermis of Hassan, a Syrian child
affected by a severe form of junctional epidermolysis bul-
losa, by means of autologous, transgenic epidermal cul-
tures (Hirsch et al., 2017). Hassan’s prognosis was poor
and attempting a compassionate use of combined ex vivo
cell and gene therapy was the only chance for him to sur-
vive. Such therapy was still in the initial phases of clinical
trials. While flying back to the Burn Unit in Bochum
10 days after the first transplantation, we and Sergio Bon-
danza, our historical ‘‘cell grower,’’ could not even talk
each other. The appearance of a pink and nice epidermis
upon removal of bandages from the grafted area was pro-
foundly moving, perhaps the strongest emotion we had
in our entire scientific career, and confirmed how awesome
science can be. We understood that Hassan’s life could be
saved.
We will tell more about Hassan’s story and scientific out-
comes, but it is important to stress that this achievement
did not come out of the blue. It was the culmination of de-
cades of hard work.
In the mid-1980s, Michele De Luca was a young MD and
endocrinologist working as a postdoc on thyroid cells at the
NIH in Bethesda. He received a job offer from Ranieri Can-
cedda, who was heading a tissue engineering laboratory
in the newly established National Cancer Institute (IST)
in Genova, Italy. Cancedda, knowing Michele’s interest in
epithelial cells, drew his attention to a paper just published
on the New England Journal of Medicine, where Howard
Green (Harvard Medical School) reported on life-saving
regeneration of the epidermis in two severely burned chil-1026 Stem Cell Reports j Vol. 11 j 1026–1033 j November 13, 2018 j ª 2018
This is an open access article under the CC BY license (http://creativecommodren by means of autologous epidermal cultures (Gallico
et al., 1984). Michele couldn’t believe it! He read all Green’s
basic papers behind that extraordinary piece of work,
including the first established protocol for primary kerati-
nocyte cultures (Rheinwald andGreen, 1975), and tortured
Howard Green until he accepted him in his lab.When back
in Italy, in 1986,Michele forgot about thyroid and endocri-
nology and initiated his work on epidermal keratinocytes.
Almost at the same time Graziella Pellegrini, after twomas-
ter degrees in Chemistry and Pharmacy, fascinated by cell
and tissue cultures, left her previous research on neuro-
pharmacology to join the laboratory of Ranieri Cancedda.
Two years later, Michele and Graziella began working
together on human squamous epithelia aimed at regenera-
tive medicine, and they still are.Epithelial Stem Cell-Mediated Cell Therapy
We dedicated the first years in Genova to growing
epidermal keratinocytes for the treatment of massive, life-
threatening full-thickness skin burns. That was quite an
exciting period; many patients were saved in collaboration
with many Burn Units inside and outside Italy (De Luca
et al., 1989; Pellegrini et al., 1999b). However, many pa-
tients were lost, due to the infancy of the entire technology
(De Luca et al., 2006). We can’t forget the first patient in
Genova and how challenging it was to simultaneously
treat, in collaboration with the Burn Unit in Turin, five
youngmen receiving flame burns on the New Year evening
in 1990, as we prepared approximately 500 cultured
epidermal grafts in 2 months. We still remember all our
traveling, taking the epidermal grafts to the numerous
Burn Units and working in close contact with plastic
surgeons.
We soon realized that primary epidermal cultures con-
tainedmelanocytes in close contact with growing keratino-
cyte colonies. We discovered that human keratinocytes
strongly induce melanocyte proliferation, which requires
keratinocyte contact and is highly regulated to maintain
a physiological keratinocyte/melanocyte ratio. We found
that only epidermal keratinocytes have all the information
required for the proper physiological organization of mela-
nocytes in the basal layer of the epidermis (De Luca et al.,
1988). These findings were the basis for a new clinical
application of epidermal cultures, developed initially inThe Author(s).
ns.org/licenses/by/4.0/).
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l’Immacolata (IDI), where wemoved in 1996. Patients with
stable vitiligo or piebaldism have been successfully treated
with cultures optimized to contain a physiological number
of melanocytes. The healed epidermis became populated
by melanocytes, and stable repigmentation has been at-
tained in those patients (Guerra et al., 2000, 2004).
Meanwhile, we developed cultures of urethral epithe-
lium, which were successfully applied to regenerate the
urethra of children carrying posterior hypospadias, acongenital defect in which the urethra terminates on the
ventral surface of the penis (Romagnoli et al., 1990, 1993).
Even though neither Green nor us called cultured kerati-
nocytes stem cells at that time, these human keratinocytes
fit the definition of stem cells as we know them today. In
those years, by clonal analysis of primary epidermal cul-
tures, Yann Barrandon and Howard Green identified three
types of clonogenic keratinocytes, giving rise to holo-
clones, meroclones, and paraclones (Barrandon andGreen,
1987). Over the years, Barrandon’s group and we haveStem Cell Reports j Vol. 11 j 1026–1033 j November 13, 2018 1027
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hallmarks of stem cells and generate meroclones and para-
clones that have properties expected of transient ampli-
fying progenitors (Dellambra et al., 2000; Pellegrini et al.,
1999a, 1999b, 2001; Rochat et al., 1994; Ronfard et al.,
2000).
We applied this notion to a new cell therapy that we
initially investigated in Genova at the Center of Advanced
Biotechnology (CBA) and further developed first in Rome
(IDI), then at the Veneto Eye Bank Foundation in Venice,
and finally at the University of Modena and Reggio Emilia
(Unimore), where we moved in 2007. We are referring to
the use of limbal stem cells for the treatment of severe
ocular burns.
Stem cells of the limbus, the narrow zone between the
cornea and the bulbar conjunctiva, underpin repair and
renewal of the corneal epithelium (Cotsarelis et al., 1989;
Schermer et al., 1986). Massive chemical ocular burns
may destroy the limbus, causing limbal stem cell defi-
ciency. The cornea acquires an epithelium through the
invasion of bulbar conjunctival cells, which leads to neo-
vascularization, chronic inflammation, stromal scarring,
corneal opacity, and loss of vision. The only way to prevent
this invasion is to restore a normal limbal/corneal epithe-
lium (Kenyon and Tseng, 1989). We initially analyzed the
entire human ocular surface and found that holoclones,
meroclones, and paraclones constitute also the prolifera-
tive compartment of the ocular epithelium. Corneal holo-
clone-forming cells are strictly segregated in the limbus.
Conjunctival holoclones are uniformly distributed in
bulbar and forniceal conjunctiva and are bipotent, in that
they generate goblet cells at least twice in their life and at
rather precise times of their life history, hence through an
intrinsic ‘‘cell-doubling clock,’’ whose molecular mecha-
nism is still unclear (Pellegrini et al., 1999a).
An important step toward determining criteria for stem
cell content of limbal cultures came from the discovery of
p63 (Yang et al., 1998) as a key transcription factor sustain-
ing all squamous epithelia (Mills et al., 1999; Senoo et al.,
2007; Yang et al., 1999).
We discovered that DNp63a is highly expressed in holo-
clones, strongly declines during clonal transition from
holoclone to meroclone, and is virtually absent from para-
clones. In the uninjured surface of the eye, DNp63a is
present in the limbus but absent from the corneal epithe-
lium. Upon corneal wounding, cells originating from the
limbus and containing DNp63a migrate progressively
through the epithelium of the peripheral and central
cornea. In the absence of an attached limbus, no DNp63a
appears in the corneal epithelium. During this wound-
healing process, DNp63b and DNp63g appear and correlate
with corneal regeneration and differentiation. Accordingly,
clonal evolution is marked by a progressive enrichment in1028 Stem Cell Reports j Vol. 11 j 1026–1033 j November 13, 2018DNp63b and DNp63g (Di Iorio et al., 2005; Pellegrini et al.,
2001). In analyzing the function of p63, we also found that
self-renewing human limbal stem cells can be identified by
the co-expression of DNp63a, C/EBPd, and Bmi1, rather
than DNp63a alone. DNp63a+/C/EBPd limbal cells main-
tain their regenerative capability but have lost their self-
renewal. DNp63a+/C/EBPd limbal cells still maintain
essential stem cell features, inasmuch as enforced expres-
sion of C/EBPd indefinitely sustains the self-renewal
of DNp63a+ cells but cannot rescue self-renewal in clono-
genic DNp63a cells. Thus, DNp63a is essential for the
proliferative/regenerative capacity of limbal stem cells,
while C/EBPd (and Bmi1) sustain their self-renewal in a
DNp63a+ genetic background (Barbaro et al., 2007).
Altogether, these findings paved the way for the first
therapeutic use of autologous limbal cultures for the per-
manent regeneration of a functional corneal epithelium,
leading to recovery of visual acuity not only in patients
with unilateral limbal stem cell deficiency but also in those
with severe bilateral corneal damage (Pellegrini et al., 1997;
Rama et al., 2001, 2010). Indeed, 1–2mm2 of spared limbus
in one eye is sufficient to generate limbal cultures able to
restore the corneal epithelium of both eyes (Rama et al.,
2010). Neither total number of limbal clonogenic cells
nor colony size or epithelial cell growth rate could predict
clinical outcomes, confirming that the vast majority
(95%) of clonogenic keratinocytes (meroclones and para-
clones) behave as transient progenitors (Pellegrini et al.,
2013). This does not mean that the number of clonogenic
cells is an irrelevant parameter, in that transient progeni-
tors surrounding epidermal stem cells are instrumental to
proper stem cell function, particularly during tissue regen-
eration (Hsu et al., 2014).
Determination of DNp63a abundance in holoclones
made it possible to prospectively evaluate the number of
stem cells in a limbal culture by computerized biparametric
analysis of the cell size and the intensity of p63 staining of
single cells (Di Iorio et al., 2006). Strikingly, the clinical suc-
cess of limbal cultures was strictly related to a precise num-
ber of stem cells, defined as p63bright holoclones (Pellegrini
et al., 2013; Rama et al., 2010). To date, no other proposed
(or supposed) limbal stemcellmarkercorrelateswithclinical
success of limbal cultures and long-term corneal stability.
In 2015 (almost 20 years after the first proof of principle
and hundreds of treated patients), our autologous limbal
cultures were complying with the new standards of Euro-
pean regulation and became the first stem cell-based cell
therapy to receive marketing authorization from the Euro-
pean Medicine Agency (Holoclar).
But this was quite a bumpy ride. Indeed, in 2007, while
dealing with intense clinical application of limbal cultures
(in collaboration with over 20 ophthalmology depart-
ments) and our first clinical trial on gene therapy of
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by the European Community, stating that ex vivo cell and
gene therapy should be considered as advanced therapy
medicinal products (ATMPs) and regulated as pharmaceu-
tical drugs. To be approved, in addition to formal clinical
trials, ATMPs needed to fulfill goodmanufacturing practice
(GMP), good clinical practice (GCP)—globally referred to as
GxPs—requirements, and deal with a variety of docu-
ments, including the Common Technical Document. We
had to stop all our translational activities and we even
thought about giving up: we did not have any GMP-certi-
fied laboratory and, more importantly, we realized that
the pharmaceutical world with its rules was a different
world, requiring a way of thinking and operating quite
far from a scientist’s mentality. We still remember a long
phone call with Howard Green (who wanted to write to
the Italian Prime Minister) who, at the end of the phone
call, just told us: ‘‘you cannot afford to let people down
just like that. You have quite a responsibility toward
many people with untreatable diseases that you know
you can at least try to tackle. You just have to keep going.’’
He was H (as all his postdocs called him), and we could not
say ‘‘no’’ to H as he had been mentoring us for years.
Fortunately, with the help of the ‘‘Fondazione Cassa di
Risparmio di Modena’’ (a local Bank Foundation), our Uni-
versity, and Stefano Ferrari (the late Dean of our Faculty),
wewere able to build the newCenter for RegenerativeMed-
icine ‘‘Stefano Ferrari’’ (CMR) containing a large GMP facil-
ity. We linked up with Chiesi, a pharmaceutical company
in nearby Parma that helped us to create a spin-off biotech,
Holostem Terapie Avanzate (HTA). We can’t thank enough
Andrea and Paolo Chiesi for getting involved in this enter-
prise. HTA took on the regulatory challenges and made our
product compliant with GMP rules. Slowly we came to un-
derstandwhat the EuropeanMedicines Agency and our na-
tional regulators (AIFA) were afraid of and demanding, and
we began planning experiments to give them the reassur-
ances they needed. Overall, however, we lost many years
during which also our scientific production decreased sub-
stantially, due to the regulatory-type activities we had to
perform. Were these requirements appropriate? Yes,
because of the improper use of stem cells. While we were
working on the construction and certification of the
CMR, we were fighting the ‘‘Stamina case’’ in Italy, as
worried members of our scientific community (Bianco
et al., 2013). The Stamina case has made Italy a battlefield
for local and international commercial interests and anti-
regulatory lobbies. Italy came close to deregulating mesen-
chymal stromal cell ‘‘therapies’’ by reclassifying them as
transplants, which would have bypassed all the above reg-
ulations and opened the way to peddlers of unproven ther-
apies (Bianco et al., 2013). We and other Italian scientists
fortunately blocked this. The 2014 Public Service Award,later granted to Paolo Bianco, Elena Cattaneo, andMichele
De Luca by the International Society for StemCell Research
(ISSCR), is a token of the global impact of the issues, as
raised by many similar cases around the world.
Combined Ex Vivo Cell and Gene Therapy of
Junctional Epidermolysis Bullosa
At the beginning of the 1990s, when still inGenova at CBA,
we decided to develop epidermal stem cell-mediated com-
bined ex vivo cell and gene therapy. The first successful
attempt to introduce and express foreign genes into pri-
mary human keratinocytes dates back to 1987 (Morgan
et al., 1987). We first demonstrated stable transduction of
epidermal stem cells with cDNA carrying b-galactosidase
and interleukin-6, the latter secreted in the bloodstream
(Mathor et al., 1996). Looking for a skin disease that could
be tackled by gene therapy, we came across epidermolysis
bullosa (EB). When you know EB kids, they get under
your skin. It is really heartbreaking dealing with them. EB
is a group of devastating, sometimes early lethal, genetic
disorders characterized by structural and mechanical
fragility of skin andmucosal membranes, highly impairing
the quality of life. There is no cure for EB. The available
symptomatic treatments are palliative and can only relieve
the ravaging clinical manifestations.
Again, it took many years of investigations before a suc-
cessful clinical trial was realized. We and others initially
discovered that a6b4 integrins mediate adhesion of basal
epidermal keratinocytes to the basement membrane at
hemidesmosomes (De Luca et al., 1990; Pellegrini et al.,
1992; Sonnenberg et al., 1991; Stepp et al., 1990). It has
since been uncovered that laminin-5 (now renamed lami-
nin-332) is the primary bridge between hemidesmosomal
a6b4 integrins and typeVII collagen, themajor component
of dermal anchoring fibrils (Rousselle et al., 1997). In turn,
collagen XVII (also known as bullous pemphigoid antigen
180) links a6b4 integrins to basal keratinocytes intermedi-
ate filaments through plectin and BP230 (Borradori et al.,
1997; Hopkinson and Jones, 2000), hence completing the
adhesion machinery tightening human epidermis to the
underlying dermis. To our knowledge, Elaine Fuchs was
the first to demonstrate that mutations in genes encoding
one component of the above adhesion machinery, namely
KRT5 and KRT14, cause EB simplex (EBS), the most com-
mon form of EB (Coulombe et al., 1991; Vassar et al.,
1991). It was then quite natural to discover that mutations
in virtually all genes forming the hemidesmosomal adhe-
sion machinery were responsible for different forms of EB
(see Fine et al., 2014 for a review).
There are four major types of EB defined by ultrastruc-
tural sites of blister formation, genetics, mode of inheri-
tance, and clinical manifestations. EBS is predominantly
due to mutations in keratin 5 and 14 and plectin.Stem Cell Reports j Vol. 11 j 1026–1033 j November 13, 2018 1029
Stem Cell Reports
PerspectiveDystrophic EB is due to mutations in COL7A1, the gene
encoding collagen VII. The absence (or alteration) of
anchoring fibrils induces blister formation at the level of
the lamina densa and is characterized by severe scarring.
Kindler syndrome is due tomutations in the gene encoding
kindling-1, a focal contact protein expressed in basal kera-
tinocytes. We decided to tackle generalized junctional EB
(JEB). In JEB, blisters and erosions of the skin and mucosa
occur within the lamina lucida of the basement membrane
in response tominor trauma.Massive chronic skin wounds
greatly impair patients’ quality of life, lead to recurrent in-
fections, and predispose patients to skin cancer. JEB is
caused by mutations in three genes—LAMA3, LAMB3, or
LAMC2—that jointly encode laminin-332 (a heterotri-
meric protein, consisting of a3, b3, and g2 chains) and in
genes encoding collagen XVII and a6b4 integrins. More
than 40% of patients die before adolescence (Fine et al.,
2008).
We first demonstrated genetic and functional correction
of LAMB3-derived epidermal stem cells in vitro (Dellambra
et al., 1998). After joining Unimore, we performed a phase
I/II clinical trial on LAMB3-dependent JEB, which provided
compelling evidence that local transplantation of trans-
genic epidermal cultures, genetically modified by a retro-
viral vector expressing the full-length LAMB3 cDNA, can
generate a functional epidermis, leading to permanent
(follow-up to date being 13 years) correction of JEB skin le-
sions (De Luca et al., 2006; De Rosa et al., 2014). However,
we had to put our trial on hold because of the new regula-
tions issued in 2007. In 2014, we resumed our trial by
treating, in collaboration with the EB House and the
Dermatology Department in Salzburg, a selected body site
of a LAMB3-JEB patient, and confirmed the clinical success
observed with the first trial (Bauer et al., 2017).
Nowwe can return to Hassan, who allowed a big leap for-
ward for the development of EB gene therapy. The story of
Hassan is touching. He suffers from a severe form of JEB,
which could not be controlled in Syria because of the civil
war. After a period in Lebanon, his family escaped from that
difficult situation and was welcomed in Germany. For a
number of reasons, it was too late to control Hassan’s
disease, which progressively worsened. Due to massive
generalized infection from Staphylococcus aureus and Pseu-
domonas aeruginosa, Hassan lost most of his skin. In 2015,
the child was admitted to the Burn Unit of the Children’s
Hospital at Ruhr University in Bochum, Germany. Tobias
Hirsch, Tobias Rothoeft, Norbert Teig, and the entire clin-
ical staff did an awesome job to keep him alive, but all ther-
apeutic attempts failed and Hassan’s prognosis was very
poor. Our German colleagues then contacted us for a last
experimental attempt. After obtaining authorization from
German regulatory authorities, literally the entire CMR in
Modena (from University staff to HTA personnel) was1030 Stem Cell Reports j Vol. 11 j 1026–1033 j November 13, 2018concentrated on this enterprise. We generated almost
1 m2 of transgenic epidermal cultures and flew to Bochum,
where these grafts were applied in collaboration with the
German clinicians, with two big surgical procedures in
2 months.
Such combined ex vivo cell and gene therapy has proved
to be life saving, inasmuch as it was able to regenerate virtu-
ally the entire epidermis of Hassan (Hirsch et al., 2017). At
the last follow-up, almost 3 years after grafting (i.e., over
30 cycles of epidermal renewal), Hassan’s transgenic
epidermis expressed normal levels of laminin-332, had
normal thickness and continuity of the basement mem-
brane, and normal morphology of hemidesmosomes
(Hirsch et al., 2017). Hassan’s transgenic epidermis is
robust and resistant to mechanical stress and does not
develop blisters or erosions. Hassan is currently leading a
normal social life. He is exercising, playing soccer, and
injuring himself with normal wound healing. Currently
we and others have initiated several ex vivo gene therapy
clinical trials trying to tackle different forms of EB (Siprash-
vili et al., 2016).
Genome-wide integration profile of his transgenic
epidermis confirmed the absence of clonal selection both
in vitro and in vivo. Indeed, Hassan received43 108 trans-
genic clonogenic keratinocytes and did notmanifest tumor
development or other related adverse events (Hirsch et al.,
2017). The transgenic nature of the regenerated epidermis,
the notion that proviral integrations provide a clonal ge-
netic mark, and the possibility to analyze clonogenic kera-
tinocytes at clonal level helped to solve a controversy in the
field. By clonal tracing experiments, we formally proved
that human epidermis is sustained only by a limited num-
ber of long-lived stem cells detected as holoclones that give
rise to pools of short-lived progenitors (meroclones and
paraclones), which persist for various periods of time,
replenish differentiated cells, and make short-term contri-
butions to wound healing (Hirsch et al., 2017). Until
then, this notion was sustained only by indirect, though
compelling, evidence (Pellegrini et al., 1999b; Ronfard
et al., 2000), including the observation that clinical success
of limbal cultures requires a defined percentage of p63bright
holoclones (Pellegrini et al., 2013; Rama et al., 2010). This
last notion is highly relevant, in that it shows that the
essential feature of any epithelial grafts is the presence of
holoclone-forming cells, which are instrumental for long-
term epidermal renewal. After this criterion is met, success
depends exclusively on clinics. Most likely, the loss of hol-
oclone-forming cells, supposedly due to improper culture
conditions, accounts for some failures of long-term epithe-
lial regeneration by means of epidermal and corneal cul-
tures (De Luca et al., 2006).
This is the essence of our scientific career, which led us to
be chosen to receive the 2018 ISSCR Award for Innovation.
Stem Cell Reports
PerspectiveThere is no greater honor for us than to be recognized by
top scientists working in our same field, scientists for
whom we have enormous respect and esteem; scientists
who stated that this prestigious award was motivated by
our perseverance in trying to combine basic science and
highly controlled translation medicine to help people
with virtually untreatable disease. While struggling with
regulations and climbing the steep, long, and winding
road toward clinical translation of such advanced thera-
pies, we also had to fight quacks selling unproven ‘‘stem’’
cell therapies. As our colleagues told us while congratu-
lating us for this award, we also hope that our work could
provide young scientists with a blueprint that can lead
them to successfully develop other fields of regenerative
medicine. The past decade has been marked by other
stem cell-based therapies producing remarkable clinical
results on incurable diseases, such as hematopoietic stem
cell gene therapy of immunodeficiencies, Wiskott-Aldrich
syndrome, or metachromatic leukodystrophy (Aiuti et al.,
2009, 2013; Biffi et al., 2013; Cavazzana-Calvo et al.,
2000). In 2016, gene therapy for adenosine deaminase
severe combined immunodeficiency became the first
stem cell-based gene therapy to receive marketing authori-
zation from the European Medicine Agency (Strimvelis).
But we are also witnessing an exponential growth of
improper use of ATMPs that, inmost cases, lacks a scientific
rationale and whose preclinical safety and efficacy are un-
clear and inconclusive. As expected, they were not effica-
cious and often detrimental for the patients and the whole
field of stem cell-based regenerativemedicine (Bianco et al.,
2013).
We could not imagine focusing on any science not
involving our beloved keratinocytes and their use in regen-
erative medicine. Thus, our heartfelt thanks go to our
Chiesi/Holostem industrial partners, who are trying to
turn our science into real therapies for all people suffering
from such severe diseases, and to the many clinicians
collaborating in the development of different fields of
regenerative medicine. Our last thought, however, goes to
the numerous BSc and PhD students, postdocs, techni-
cians, and staff we had the honor to mentor in these years.
They were and are our victims, since they too had to love
keratinocytes before being allowed to work with them.
They are too many to be named, but without them all
this work would not have been possible. It would be hypo-
critical to deny that some of them have been and are
special.ACKNOWLEDGMENTS
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